Advanced

miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients.

Hagman, Zandra LU ; Haflidadottir, Benedikta LU ; Ceder, Jens LU ; Larne, Olivia LU ; Bjartell, Anders LU ; Lilja, Hans LU ; Edsjö, Anders LU and Ceder, Yvonne LU (2013) In British Journal of Cancer 108(8). p.1668-1676
Abstract
Background:The microRNA-205 (miR-205) has been shown to be deregulated in prostate cancer (PCa). Here we continue to investigate the prognostic and therapeutic potential of this microRNA.Methods:The expression of miR-205 is measured by qRT-PCR and in situ hybridisation in a well-documented PCa cohort. An AGO2-based RIP-Chip assay is used to identify targets that are verified with western blots, luciferase reporter assay, ELISA and immunohistochemistry.Results:The expression of miR-205 is inversely correlated to the occurrence of metastases and shortened overall survival, and is lower in castration-resistant PCa patients. The miR-205 expression is mainly localised to the basal cells of benign prostate tissues. Genes regulated by miR-205 are... (More)
Background:The microRNA-205 (miR-205) has been shown to be deregulated in prostate cancer (PCa). Here we continue to investigate the prognostic and therapeutic potential of this microRNA.Methods:The expression of miR-205 is measured by qRT-PCR and in situ hybridisation in a well-documented PCa cohort. An AGO2-based RIP-Chip assay is used to identify targets that are verified with western blots, luciferase reporter assay, ELISA and immunohistochemistry.Results:The expression of miR-205 is inversely correlated to the occurrence of metastases and shortened overall survival, and is lower in castration-resistant PCa patients. The miR-205 expression is mainly localised to the basal cells of benign prostate tissues. Genes regulated by miR-205 are enriched in, for example, the MAPK/ERK, Toll-like receptor and IL-6 signaling pathways. We demonstrate binding of miR-205 to the 3'UTR of androgen receptor (AR) and decrease of both AR transcript and protein levels. This finding was corroborated in the patient cohort were miR-205 expression inversely correlated to AR immunostaining in malignant prostate cells and to serum levels of prostate-specific antigen, an androgen-regulated protein.Conclusion:Taken together, these findings imply that miR-205 might have therapeutic potential, especially for the castration resistant and currently untreatable form of PCa.British Journal of Cancer advance online publication, 9 April 2013; doi:10.1038/bjc.2013.131 www.bjcancer.com. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Cancer
volume
108
issue
8
pages
1668 - 1676
publisher
Nature Publishing Group
external identifiers
  • wos:000318406400015
  • pmid:23571738
  • scopus:84877017881
ISSN
1532-1827
DOI
10.1038/bjc.2013.131
language
English
LU publication?
yes
id
ec1c658f-67b3-4659-a7bc-f681a328f3da (old id 3733987)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23571738?dopt=Abstract
date added to LUP
2013-05-04 17:23:12
date last changed
2019-08-28 01:36:48
@article{ec1c658f-67b3-4659-a7bc-f681a328f3da,
  abstract     = {Background:The microRNA-205 (miR-205) has been shown to be deregulated in prostate cancer (PCa). Here we continue to investigate the prognostic and therapeutic potential of this microRNA.Methods:The expression of miR-205 is measured by qRT-PCR and in situ hybridisation in a well-documented PCa cohort. An AGO2-based RIP-Chip assay is used to identify targets that are verified with western blots, luciferase reporter assay, ELISA and immunohistochemistry.Results:The expression of miR-205 is inversely correlated to the occurrence of metastases and shortened overall survival, and is lower in castration-resistant PCa patients. The miR-205 expression is mainly localised to the basal cells of benign prostate tissues. Genes regulated by miR-205 are enriched in, for example, the MAPK/ERK, Toll-like receptor and IL-6 signaling pathways. We demonstrate binding of miR-205 to the 3'UTR of androgen receptor (AR) and decrease of both AR transcript and protein levels. This finding was corroborated in the patient cohort were miR-205 expression inversely correlated to AR immunostaining in malignant prostate cells and to serum levels of prostate-specific antigen, an androgen-regulated protein.Conclusion:Taken together, these findings imply that miR-205 might have therapeutic potential, especially for the castration resistant and currently untreatable form of PCa.British Journal of Cancer advance online publication, 9 April 2013; doi:10.1038/bjc.2013.131 www.bjcancer.com.},
  author       = {Hagman, Zandra and Haflidadottir, Benedikta and Ceder, Jens and Larne, Olivia and Bjartell, Anders and Lilja, Hans and Edsjö, Anders and Ceder, Yvonne},
  issn         = {1532-1827},
  language     = {eng},
  number       = {8},
  pages        = {1668--1676},
  publisher    = {Nature Publishing Group},
  series       = {British Journal of Cancer},
  title        = {miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients.},
  url          = {http://dx.doi.org/10.1038/bjc.2013.131},
  volume       = {108},
  year         = {2013},
}